	US 11,655,292 B2
	Anti-human NGF antibodies and methods using same
Zhu Wang, Shanghai (CN); Yongjuan Gao, Shanghai (CN); Si Chen, Shanghai (CN); Cecily Rou-Yun Sun, Shanghai (CN); Yuncheng Zheng, Shanghai (CN); Bill Nai-Chau Sun, Shanghai (CN); and Qiang Li, Shanghai (CN)
Assigned to AMPSOURCE BIOPHARMA SHANGHAI INC., Shanghai (CN)
Filed by AMPSOURCE BIOPHARMA SHANGHAI INC., Shanghai (CN)
Filed on Jun. 23, 2020, as Appl. No. 16/909,881.
Prior Publication US 2021/0395354 A1, Dec. 23, 2021
Int. Cl. C07K 16/22 (2006.01); A61K 38/18 (2006.01)

CPC C07K 16/22 (2013.01) [A61K 38/185 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

8 Claims

1. An antibody or an antigen binding fragment thereof, which binds to human nerve growth factor, comprises:

a heavy chain variable region, which comprises CDR-H1, CDR-H2, and CDR-H3; and

a light chain variable region, which comprises CDR-L1, CDR-L2 and CDR-L3 wherein: said CDR-H1 comprises an amino acid sequence as shown in SEQ ID NO: 1, said CDR-H2 comprises an amino acid sequence as shown in SEQ ID NO: 3, said CDR-H3 comprises an amino acid sequence as shown in SEQ ID NO: 5, said CDR-L1 comprises an amino acid sequence as shown in SEQ ID NO: 7, said CDR-L2 comprises an amino acid sequence having Tyr-Thr-Ser (Tyrosine— Threonine— Serine), and said CDR-L3 comprises an amino acid sequence as shown in SEQ ID NO: 11.